Veracyte
Veracyte, Inc., a leading genomic diagnostics company headquartered in the United States, is at the forefront of transforming patient care through innovative solutions. Founded in 2013, Veracyte has made significant strides in the field of molecular diagnostics, particularly in oncology and pulmonary diseases. The company’s core offerings include advanced genomic tests that provide critical insights for accurate disease diagnosis and management, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Veracyte has established itself as a trusted partner for healthcare providers. Notable achievements include the development of unique tests that enhance the diagnostic process, thereby improving patient outcomes. As a pioneer in the industry, Veracyte continues to lead the way in precision medicine, making significant contributions to the evolving landscape of genomic healthcare.
DitchCarbon Score
How does Veracyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veracyte's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Veracyte's reported carbon emissions
Veracyte, Inc., headquartered in the United States, currently does not report any specific carbon emissions data for the latest year. As of May 2024, the company has committed to near-term climate targets, although no specific reduction targets or net-zero commitments have been established. Veracyte operates within the Healthcare Providers and Services sector, and its climate initiatives are aligned with industry standards. The company is actively engaged in climate commitments, as indicated by its participation in the Science Based Targets initiative (SBTi), where it has been classified as "Committed" to near-term targets. However, details regarding specific emissions reductions or long-term targets remain unspecified. As Veracyte continues to develop its climate strategy, it is essential for stakeholders to monitor its progress and future commitments in the context of the broader healthcare technology sector's efforts to address climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Veracyte is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
